1. Home
  2. REXR vs CORT Comparison

REXR vs CORT Comparison

Compare REXR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rexford Industrial Realty Inc.

REXR

Rexford Industrial Realty Inc.

HOLD

Current Price

$37.01

Market Cap

8.4B

Sector

Real Estate

ML Signal

HOLD

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

SELL

Current Price

$113.68

Market Cap

9.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
REXR
CORT
Founded
2013
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4B
9.7B
IPO Year
2013
2001

Fundamental Metrics

Financial Performance
Metric
REXR
CORT
Price
$37.01
$113.68
Analyst Decision
Hold
Buy
Analyst Count
10
5
Target Price
$41.00
$96.50
AVG Volume (30 Days)
2.1M
1.0M
Earning Date
04-23-2026
04-30-2026
Dividend Yield
4.90%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.09
Revenue
$1,003,133,000.00
$761,407,000.00
Revenue This Year
$0.09
$26.08
Revenue Next Year
$2.99
$26.98
P/E Ratio
N/A
$1,299.22
Revenue Growth
7.13
12.79
52 Week Low
$32.14
$28.66
52 Week High
$44.38
$126.38

Technical Indicators

Market Signals
Indicator
REXR
CORT
Relative Strength Index (RSI) 52.48 55.51
Support Level $34.75 $76.41
Resistance Level $37.87 $122.21
Average True Range (ATR) 0.60 3.86
MACD -0.02 -1.00
Stochastic Oscillator 57.78 29.60

Price Performance

Historical Comparison
REXR
CORT

About REXR Rexford Industrial Realty Inc.

Rexford Industrial Realty Inc is a real estate investment trust focused on owning, operating and acquiring industrial properties in Southern California infill markets. Its goal is to generate attractive risk-adjusted returns for the stockholders by providing superior access to industrial property investments and mortgage debt investments secured by industrial property in high-barrier Southern California infill markets. The company generates revenue from rental income derived from properties in its portfolio.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: